Safinamide is a monoamine oxidase‑B (MAO‑B) inhibitor. It received a European marketing authorisation in February 2015 and was launched in the UK in May 2016. It is licensed for treating mid- to late-stage idiopathic Parkinson's disease in adults who are experiencing motor fluctuations, as an add-on treatment to a stable dose of levodopa when used either on its own or in combination with other Parkinson's disease medicines.